Anacor slashes IPO share price; Genzyme meets key deadline on plant decree; Gilead files for approval of combo HIV drug

 @FierceBiotech: Uphill climb gets even steeper for biotech IPOs. Report | Follow @FierceBiotech

 @JohnCFierce: A few weeks ago Amira's Bob Baltera was brimming with confidence about new financing. Today, not so much. Story | Follow @JohnCFierce

> Anacor has priced its IPO, slashing the price and boosting the number of shares on offer as it confronts a chilly reception for classic biotech offerings. Anacor says it will sell 12 million shares at $5 apiece rather than 4.7 million shares for $16 to $18 each. Report

> Genzyme says it met a key component of its consent decree with federal regulators, ending filling and finishing work at the targeted manufacturing facility. Story

Special Report: FierceBiotech's 2010 Fierce 15.  Report

> Gilead filed for regulatory approval of a new combo HIV therapy which matches Truvada with Tibotec's rilpivirine. Story

> Grifols says it has obtained the loans it needs to buy Talecris. Item

Special Report: The Top 10 Phase III Failures of 2010. Report

And Finally... Binghamton University researchers recently revived ancient bacteria trapped for thousands of years in water droplets embedded in salt crystals. Binghamton University release

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.